## MINUTES OF THE COMMITTEE ON TORT REFORM

Tuesday, June 6, 2006 9:30 a.m. Rooms 502/519, House Office Building

The House Standing Committee on Tort Reform was called to order by the Chair, Representative Elsenheimer.

Members present: Representatives Elsenheimer, Kahn, Gaffney, Huizenga, Hune, Adamini, McConico, Bieda.

Chairman Elsenheimer announced that the purpose of the day's meeting would be a video conference with the United States Food and Drug Administration (FDA) regarding the drug approval process.

The following individuals from the FDA participated in the video conference with the committee:

- -Bronwyn Collier, B.S.N., Associate Director for Regulatory Affairs, Office of Drug Evaluation III, Center for Drug Evaluation and Research.
- -Nancy Boocker, Director of the Division of Regulatory Policy I, Center for Drug Evaluation and Research.

Ms. Collier gave an overview of the drug approval process and the application integrity policy.

Ms. Boocker provided an explanation and overview of the citizen petition process.

Both Ms. Collier and Ms. Boocker then took questions from committee members.

Representative Kahn moved to approve the minutes of the meeting held on May 23, 2006. Representative Hune supported the motion. There being no objection the minutes were approved by unanimous consent.

The Chairman placed the committee at ease, the time being 10:30 a.m., in order to facilitate continued public viewing of the committee meeting.

The Chairman called the meeting back to order at 10:35 a.m.

The committee continued with a question and answer session with the representatives of the FDA.

Sheila Bokenkotter, representing Drug Industry Immunity Must End, submitted written material to the committee.

There being no	further business	before the	committee,	the Chair	adjourned	the n	neeting	ai
10:50 a.m.								

Repre	esentative	Kevin	Elsenheimer	, Chair	•

Doug Simon, Committee Clerk
House Tort Reform Committee, (517) 373-0015